AIMLogo.jpg
Hemispherx Biopharma Announces Financial Results for the Nine Months Ended September 30, 2015
17 nov. 2015 08h30 HE | AIM ImmunoTech Inc.
PHILADELPHIA, Nov. 17, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announced its financial results for the nine months ended September 30, 2015. The net loss (including non-cash...
EquelsHEBBioReactor.jpg
Hemispherx Biopharma Europe N.V./S.A. Receives Positive Opinion on Application for Orphan Designation by the European Medicines Agency for Alferon N Injection to Treat Patients With Middle East Respiratory Syndrome (MERS)
19 oct. 2015 08h30 HE | AIM ImmunoTech Inc.
PHILADELPHIA, Oct. 19, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announces that the European subsidiary, “Hemispherx Biopharma Europe...
AIMLogo.jpg
New Arrowhead Analyst Issues Updated Diligence and Valuation Report on Hemispherx Biopharma
30 sept. 2015 08h30 HE | AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 30, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announces that Arrowhead BID issued an analyst report on September 29, 2015,...
AIMLogo.jpg
Hemispherx Biopharma Receives the European Patent Office Grant of New Composition of Matter Patent Covering Ampligen(R) Formulations
28 sept. 2015 08h30 HE | AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 28, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that it received formal notice on September 21, 2015, that the...
AIMLogo.jpg
Hemispherx Biopharma Reports Article by Senior Authors From Italian Ministry of Health and Related Agencies Suggesting Broad Applicability of Ampligen(R) to Multiple Sclerosis
23 sept. 2015 08h30 HE | AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 23, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today a new peer reviewed article, with senior authors from the Italian Ministry of Health and other...
AIMLogo.jpg
Hemispherx Biopharma Announces Patient Assistance Program for Chronic Fatigue Syndrome Open Label Study
17 sept. 2015 08h30 HE | AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 17, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today the approval by the Board of Directors for a Patient...
Thomas K. Equels with HEB Sign
Photo Release -- Hemispherx Biopharma Fully Aligns Executive Bonus Programs to Accelerate Product Revenue Opportunities and Market Entry
31 août 2015 08h30 HE | AIM ImmunoTech Inc.
NEW BRUNSWICK, N.J., Aug. 31, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) recently hosted a Stockholder Open House in their manufacturing and Research and Development (R&D)...
AIMLogo.jpg
Hemispherx Biopharma Europe N.V./S.A. Submits Application for Orphan Medicine Designation to the EMA for Alferon N Injection(R) for Treatment of Middle East Respiratory Syndrome (MERS)
15 juil. 2015 08h30 HE | AIM ImmunoTech Inc.
PHILADELPHIA, July 15, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announces that they have submitted an application for orphan drug designation...
AIMLogo.jpg
Hemispherx Biopharma Europe N.V./S.A.: Orphan Medicine Designation and European Medicines Agency Public Opinion Summary Published by EMA Regarding Ampligen/Rintatolimod for Ebola Virus Disease (EVD)
26 mai 2015 12h46 HE | AIM ImmunoTech Inc.
PHILADELPHIA, May 26, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announces that the European Medicines Agency (EMA) has published on May 22,...
AIMLogo.jpg
Hemispherx to Present at the Marcum Microcap Conference in New York
20 mai 2015 08h30 HE | AIM ImmunoTech Inc.
PHILADELPHIA, May 20, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) will present at the Marcum Microcap Conference being held at the Grand Hyatt Hotel in New York City on Wednesday, May...